The metabolic fate of intravenously injected vitamin D 3 -1,2-3 H (D 3 -3 H) was studied in two normal individuals on chronic phenobarbital therapy. Silicic acid column chromatography of lipid-soluble plasma extracts obtained serially for 96 hr after D 3 -3 H injection demonstrated a decreased plasma D 3 -3 H half-life and increased conversion to more polar metabolites. The polar metabolites formed included several with chromatographic mobility similar to known biologically inactive vitamin D metabolites and one with chromatographic mobility identical to 25-hydroxycholecalciferol. Disappearance of this latter material was also accelerated. A child with rickets and a normal volunteer studied before and after a 2 wk course of phenobarbital therapy demonstrated similar alterations in D 3 -3 H metabolism. When liver microsomes from 3-wk-old Sprague-Dawley rats treated with phenobarbital were incubated with D 3 -3 H, polar metabolites were produced with chromatographic mobility similar to the plasma D 3 -3 H metabolites from phenobarbital-treated humans. Similar incubations employing 25-hydroxy-cholecalciferol-26-27-3 H as the substrate also demonstrated an increased conversion to polar metabolites. The data suggest that the reported increased incidence of osteomalacia observed in patients on chronic anticonvulsant therapy may be the result of an accelerated conversion of vitamin D and its active metabolite, 25-hydroxycholecalciferol, to polar metabolites by druginduced liver microsomal enzymes. life and increased conversion to more polar metabolites. The polar metabolites formed included several with chromatographic mobility similar to known biologically inactive vitamin D metabolites and one with chromatographic mobility identical to 25-hydroxycholecalciferol. Disappearance of this latter material was also accelerated. A child with rickets and a normal volunteer studied before and after a 2 wk course of phenobarbital therapy demonstrated similar alterations in D3-'H metabolism. When liver microsomes from 3-wk-old Sprague-Dawley rats treated with phenobarbital were incubated with D3-'H, polar metabolites were produced with chromatographic mobility similar to the plasma D3-'H metabolites from phenobarbital-treated humans. Similar incubations employing 25-hydroxycholecalciferol-26,27-2H as the substrate also demonstrated an increased conversion to polar metabolites. The data suggest that the reported increased incidence of osteomalacia observed in patients on chronic anticonvulsant therapy may be the result of an accelerated conversion of vitamin D and its active metabolite, 25-hydroxycholecalciferol, to polar metabolites by druginduced liver microsomal enzymes.
INTRODUCTION
An increased incidence of rickets in children on longterm anticonvulsant therapy was first reported in 1968 by Kruse (1) . More recently, Richens and Rowe (2) have observed a striking incidence of hypocalcemia and Dr. Avioli is a Career Research Development Awardee (7-K3-GM 22-676-05). Dr. Hahn is the recipient of Public Health Service Special Fellowship 5 P03 CA39622-03.
Received for publication 20 January 1971 and in revised form 20 October 1971. elevations of serum alkaline phosphatase in an institutionalized adult epileptic population, the degree of hypocalcemia correlating positively with the total dosage of anticonvulsant drugs received. Simultaneously, Dent, Richens, Rowe, and Stamp (3) demonstrated that the osteomalacic bone changes in adults on long-term anticonvulsant therapy respond rapidly to vitamin D supplementation.
In a preliminary report (4) we have observed that human subjects on chronic phenobarbital therapy manifest an increased rate of disappearance of vitamin D3-'H (D3-'H)' from the plasma, and that liver microsomes from phenobarbital-treated animals are capable of rapidly converting D3-'H to more polar metabolites in vitro.
We now report that (a) patients on chronic phenobarbital therapy rapidly convert injected Ds-'H to more polar metabolites, some of which are metabolically inactive; (b) this increased conversion can be rapidly induced in individuals receiving a conventional dose of phenobarbital; and (c) administration of phenobarbital to rats induces increased in vitro hepatic conversion of D3-'H and 25-hydroxycholecalciferol-'H (25-OH-D3-'H to more polar metabolites, the increased conversion being associated with increased microsomal hydroxylase activity.
METHODS
Two normal adult females age 45 and 43 yr (E. D. and G. D.) who had been taking phenobarbital (90-120 mg/ day) orally in divided doses for more than 1 yr, an 11 month old male infant with previously untreated rickets (C. C.) and a 30 yr old male normal volunteer (J. H.) were used for these studies. All subjects had previously been on adequate diets containing approximately 800 IU of vitamin D and were studied during hospitalization after 7-10 days of adaptation to diets containing 800-1000 IU of vitamin D per day. C. C. and J. H. were restudied after a 2 wk course of phenobarbital, 2 mg/kg per day and 1.5 mg/kg per day, respectively, in divided oral doses. Plasma samples were subjected to combustion for determination of total 'H and extracted with methanolchloroform for determination of total lipid soluble radioactivity (5) . Chloroform extracts of 24-, 48-, 72-, and 96-hr plasma samples were also dried in a flash evaporator under nitrogen, the residue dissolved in Skellysolve B (a petroleum fraction boiling at 65-670C) (Skelly Oil Co., Tulsa, Okla.), applied to 50 X 1.5 cm silicic acid columns and chromatographed using petroleum ether-diethyl ether-methanol elution procedures as described by Ponchon and DeLuca (6). 10-ml fractions were collected with a flow rate of 1 ml/min and radioactivity monitored as previously described (5) . The interval between initial and repeat studies in C. C. and J. H. was 6 and 8 wk, respectively. Extracts of 4 ml of plasma taken just before the repeat study contained no radioactivity in C. C. and 0.04% of the injected dose confined to the peak IV region in J. H.
Plasma Ds-2H half-life as determined by column chromatography was confirmed in each subject by calculation of Da-'H half-life determined by thin-layer chromatography of plasma samples taken at the more frequent intervals noted above (5 (11) .
RESULTS
Disappearance and metabolic fate of vitsmin Ds in plasma. The plasma half-life of Da-MH as determined by silicic acid column chromatography in two otherwise normal adults (E. D. and G. D.) on chronic phenobarbital therapy (1.3-1.5 mg/kg per day) was significantly decreased when compared to a group of 12 normal adults (7 males and 5 females, aged 26-48 yr) not on phenobarbital studied under similar conditions (Table I) . Moreover, administration of phenobarbital orally for 2 wk to C. C., a child with previously untreated rickets (1.5 mg/kg per day), and J. H., a normal adult volunteer (2 mg/kg per day), resulted in 72 hr after injection of D3-3H are illustrated in Fig. 1 .
The material in peak III has been isolated previously from human plasma after D3-'H administration and identified as unaltered vitamin D3 with potent in vivo antirachitic activity (5) . In the multigradient chromatographic system employed in this study, peak IV ordinarily represents 25-OH-D3, the biologically active metabolite of vitamin D (12) . Further confirmation of the chromatographic identity of peak IV as 25-OH-D3 in these studies was obtained by adding 0.50 mg of pure 25-OH-D3 to 72-hr plasma extracts from E. D. and G. D. and applying to silicic acid columns. Fractions were collected as usual, and samples taken for measurements of optical density at 264 m/, as well as radioactivity by liquid scintillation counting. The optical density of 25-OH-D3 at 264 m/i in each case coincided exactly with the peak IV radioactivity. Additional confirmation was obtained by isolating the peak IV metabolite from silicic acid columns and rechromatographing on Celite partition columns (7) . In each instance, a single peak of radioactivity was obtained which was exactly coincident with 25-OH-D3 as determined by optical density measurements.
Normally, 25-OH-D3 is derived from vitamin Da by hydroxylation in the liver, possibly by a specific mitochondrial hydroxylase (13, 14 (Fig.  1, top) . During the second D3-8H study performed after 2 wk of phenobarbital therapy, the percentage of radio' activity in J. H.'s 72 hr plasma migrating as D3-8H was decreased and the percentage migrating as 25-OH-D3-3H (peak IV) and more polar metabolites (peak V, VI, VII) was increased. In the two normal subjects on long-term phenobarbital therapy, the changes were even more striking (Table II) .
The time course of disappearance of D3-3H and appearance of 25-OH-D3-3H and more polar metabolites in control and phenobarbital-treated subjects is illustrated in Figs. 2 and 3 . The disappearance of Ds-8H and the appearance of 25-OH-D3-3H and peaks V-VII were markedly accelerated in the phenobarbital-treated subjects. The generated 25-OH-D3-3H peak increased with time, reaching maximal value by 24 hr (1.8 times the D3-8H half-life) in the phenobarbital-treated subjects and then began to fall off rapidly. In contrast, the level of the 25-OH-D3 peak was still rising after 96 hr (3.5 times the D3-3H half-life) in control subjects. The relatively earlier onset of decay of the 25-OH-D3-3H peak suggests increased metabolism as well as more rapid appearance of this metabolite in phenobarbital-treated subjects.
The portion of plasma radioactivity occurring as aqueous-soluble metabolites was determined by subtracting plasma lipid-soluble radioactivity from total Values represent the mean +4SEM of at least five determinations. Incubation conditions were identical to those described in Table III with the substitution of 25-Ol-L-D3-3H as the substance.
phenobarbital were incubated with Di-3H and the results compared with incubations with equivalent amounts of protein nitrogen from corresponding subcellular fractions of control animals. Whereas microsomes from control animal livers had a minimal effect on D3-8H at the concentrations employed, hepatic microsomes from phenobarbital-treated animals catalyzed an accelerated conversion of D3-3H to lipid-soluble products which were more polar than 25-OH-D3-3H (Fig. 4) . Additionally, there was a 250% increase in total watersoluble vitamin D3 metabolites. These changes were associated with increased microsomal oxidation of hexobarbital (Table III) . Similarly, whereas 25-OH-D3-3H was only slightly metabolized by the liver microsomes obtained from control animals, liver microsomes obtained from phenobarbital-treated animals increased conversion of 25-OH-D3-3H to more polar metabolites (Table IV) . Incubation of either D3-3H or 25-OH-D3-3H with nuclear, mitochondrial, or cytoplasmic hepatic cell fractions from phenobarbital-treated animals demonstrated no difference from incubations with similar fractions from control animals. The metabolic products obtained from D3-'4C incubated in vitro with microsomes from phenobarbitaltreated rats were cochromatographed on silicic acid columns with the D3-3H metabolites from the plasma of the patients on chronic phenobarbital therapy (Fig. 5) . D3-'4C metabolites derived from microsome incubation had a mobility almost identical to the plasma metabolites obtained from the human subjects on phenobarbital.
DISCUSSION
The demonstration of accelerated metabolism of vitamin D3 in subjects on phenobarbital therapy would provide a rational basis for the reported increased incidence of osteomalacia in individuals on chronic anticonvulsant therapy (1, 2) . The results of the present experiments suggest that this accelerated metabolism is the result of drug-stimulated increases in hepatic microsomal activity. It has been well established that the induction of increased liver microsomal enzyme activity by phenobarbital results in decreased in vivo biologic activity of steroid compounds. Levin, Welch, and Conney demonstrated that pretreating immature female rats with phenobarbital in doses as low as 2 mg/kg per day diminished the uterotrophic response to administered estradiol or estrone, decreased the uterine concentration of injected tritiated estrogens and increased production of polar estrogen metabolites (18, 19) . Also, phenobarbital treatment has been demonstrated to decrease the seminal vesicle-stimulating effect of androgens (20) and to diminish the effect of progesterone in association with increased hepatic hydroxylation and decreased total body accumulation of the steroid and its metabolites (21) .
Similarly, induction of liver microsomal enzyme activity with diphenylhydantoin (DPH) has been demonstrated to have important clinical effects on steroid metabolism in humans. Werk (24) have reported decreased effectiveness of dexamethasone in suppressing morning plasma cortisol levels in association with increased urinary and biliary excretion of conjugated dexamethasone or its metabolites in individuals on DPH therapy.
Similarities between the drug and steroid hydroxylases in hepatic microsomes have led to the suggestion that drugs and steroids are substrates for the same hepatic P-450 enzyme system (25) . Hence, agents which increase the activity of hepatic drug-metabolizing enzymes could be expected to increase hydroxylation of steroid compounds as well. The drug-induced microsomal enzymes hydroxylate steroids predominantly at the 6P, 7a, and 16a positions (26) . Thus, the resultant steroid metabolites tend to be more polar than their parent compound. Since vitamin D3 and 25-OH-D3 are structurally similar to the steroid hormones and are readily accumulated by the liver (27, 28) , these compounds might well be expected to be metabolized to more polar products by the hepatic P-450 system. Although the polar lipid-soluble Di-'H metabolites occurring in increased proportion in phenobarbital-treated humans are as yet unidentified, their chromatographic similarity to metabolites produced by phenobarbitalinduced rat liver microsomal enzymes makes it likely that some of the human plasma metabolites are the result of increased liver microsomal activity. There are, however, quantitative differences between the metabolites produced in the in vitro D3-'H studies and those noted in the plasma of patients treated with phenobarbital. Whereas the major portion of the radioactivity in human 72-hr plasma samples occurred as 25-OH-D8, peaks V, VI, and VII were the more prominent D8-'H metabolites in the microsomal incubations.
The explanation for the observed differences in vivo and in vitro metabolites is not entirely clear. Since it has been reported that the hepatic vitamin Ds 25-hydroxylase is of mitochondrial origin, it is not surprising that the microsomal incubations in these studies did not produce significant amounts of 25-OH-Ds. On the other hand, mitochondrial fractions from phenobarbital-treated animals were likewise not found to produce increased amounts of 25-OH-D3. It is possible that differences between patterns of plasma and intracellular metabolites or differences between in vivo and in vitro pathways might account for the differences between in vivo and in vitro metabolite patterns. A more likely explanation relates to the fact that, due to accelerated microsomal metabolism, it would be anticipated that body stores of vitamin D8 and 25-OH-D3
would gradually become depleted in individuals on chronic phenobarbital therapy. Since it has been demonstrated both in rats (29) and humans (30) (34) , among others, the potential for altered vitamin D metabolism in many clinical situations is apparent. Therefore, patients on high doses of drugs known to stimulate hepatic drug-metabolizing enzymes, especially those individuals with marginal dietary intake or diseases predisposing to vitamin D malabsorption, should be carefully evaluated for evidence of vitamin D deficiency.
